2008
Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali AC, Bia MJ. Management of Cardiovascular Disease in Renal Transplant Recipients. Clinical Journal Of The American Society Of Nephrology 2008, 3: 491-504. PMID: 18287250, PMCID: PMC6631091, DOI: 10.2215/cjn.05081107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal transplant recipientsTransplant recipientsRisk factorsCardiovascular diseaseKidney Disease Outcomes Quality InitiativeCardiovascular risk factorsHigher cardiovascular mortalityMajor risk factorBest available studiesCause of deathHealth care professionalsAllograft survivalGraft lossCardiovascular eventsLifestyle modificationCardiovascular mortalityImmunosuppressive agentsDrug therapyClinical acumenGeneral populationCare professionalsMajor causeDiseaseRecipientsAvailable studies
2006
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006, 21: 1389-1394. PMID: 16431893, DOI: 10.1093/ndt/gfk058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmlodipineBlood Pressure DeterminationChi-Square DistributionDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionKidney Failure, ChronicKidney TransplantationLosartanMaleMiddle AgedProbabilityRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsRenal transplant recipientsPost-transplant periodEarly post-transplant periodARB useUse of ARBInitial therapyCCB groupImmediate post-transplant periodPost-transplant erythrocytosisPost-transplant hypertensionRisk of hyperkalaemiaPost-transplant managementSerum creatinine levelsChronic kidney diseaseII receptor blockersCalcium channel blockersNumber of patientsAldosterone systemARB groupKidney transplantationRenal transplantationTransplant recipientsCreatinine levelsRenal functionBlood pressure
2004
Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection
Friedman AL, Goker O, Kalish MA, Basadonna GP, Kliger AS, Bia MJ, Lorber MI. Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection. International Urology And Nephrology 2004, 36: 451-456. PMID: 15783123, DOI: 10.1007/s11255-004-8685-2.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsOlder patientsYounger patientsChronologic ageActual patient survival ratesOlder renal transplant recipientsPrimary kidney transplantsYear graft survivalPatient survival ratesOrgan Transplant CenterAcute rejectionCadaveric recipientsEquivalent immunosuppressionGraft survivalImmunosuppression strategiesImmunosuppressive protocolsConsecutive recipientsKidney transplantDonor kidneysTransplant centersGeriatric patientsYounger recipientsOutcome analysisStudy group
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients